Advertisement

Advertisement
Breast Cancer

T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration...


Lung Cancer

Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC

Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival...

Colorectal Cancer

Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer

First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin...


Advertisement
Colorectal Cancer

New Findings on Aspirin and Risk of Colorectal Cancer Recurrence

According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily...

Colorectal Cancer

New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer

Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors...

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Breast Cancer

Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery

Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...

Advertisement

CAR T-Cell Therapy Not Linked to Secondary Cancers, Study Finds

Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Multiple Myeloma

AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma

Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...

Lung Cancer

Getting a Lung Cancer Diagnosis Was Shocking

For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...

Potential Link Between Early Side Effects From Radiation Therapy and Long-Term Side Effects in Patients With Prostate Cancer

The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology

Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...

Advertisement

Botensilimab Plus Balstilimab in Relapsed or Refractory Metastatic Sarcomas

In a phase Ib study reported in the Journal of Clinical Oncology, Wilky et al found that the combination of botensilimab (Fc-enhanced anti–CTLA-4 antibody) and balstilimab (anti–PD-1 antibody) yielded activity in patients with relapsed or refractory metastatic sarcomas. Study Details In the trial,...

ASCO Post X Feed
Social Media Hub by Everwall